NCT02692859View on ClinicalTrials.gov

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

1,992

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Haemophilus Influenza
Interventions
BIOLOGICAL

Hib conjugate vaccine

Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose

Sponsors
All Listed Sponsors
collaborator

Chengdu Olymvax Biopharmaceuticals Inc.

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT02692859 - A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine | Biotech Hunter | Biotech Hunter